★ ANNUAL REVIEW 2027 SPONSORSHIPS NOW OPEN   Learn more →

Log In  |  Become a Member  |  Sponsor  |  ⌕ Search

News/Compliance & Enforcement/Life Sciences Companies Face Continuing Compliance Challenges in Developing Value-Based and Value-Added Models
Expert Opinion·Compliance & Enforcement Brief

Life Sciences Companies Face Continuing Compliance Challenges in Developing Value-Based and Value-Added Models

McGuireWoods – The HHS Office of Inspector General's unfavorable Advisory Opinion 23-08 continues its long-held position that the provision of value-added items and services implicates fraud and abuse laws, including the Federal Anti-Kickback Statute and the Beneficiary Inducement Civil Monetary Penalty law.

🔒 Members Only · Compliance & Enforcement BriefYou’ve reached the member portion of this brief.Members read the full analysis and the source documents in every case digest, six days a week.
Not ready to join? Take the free Pub K Weekly digest.One email. Free. Top industry articles, the community calendar, and the latest job postings.